Previous 10 |
home / stock / camrf / camrf news
Large increase in the number of patients treated with weekly and monthly Buvidal ® for opioid dependence Camurus reiterates its 2020 outlook, with sales and total revenues expected to reach the higher end of previous guidance Lund, Sweden , April 2, 2020 /PRNews...
Ra Pharmaceuticals (NASDAQ: RARX ) inks a global license agreement with Camurus AB ( OTC:CAMRF ) securing the rights to the latter's FluidCrystal technology that will enable the development of a long-acting formulation of C5 inhibitor zilucoplan for the treatment of complement-mediated dis...
FluidCrystal® extended release formulation of zilucoplan achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting at least once weekly dosing CAMBRIDGE, Massachusetts and LUND, Sweden , July 16, 2019 /PRNewswire/ -- Ra Pharmaceu...
LUND, Sweden , June 20, 2019 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX), a commercial stage biopharmaceutical company specializing in long-acting medicines for severe and chronic disorders, announced today the acceptance by the US Food and Drug Administration (FDA) of an Investigational N...
Camurus AB (publ) ( OTC:CAMRF ): Q1 GAAP EPS of -SEK1.50. More news on: Camurus AB (publ), Earnings news and commentary, Read more ...
STOCKHOLM , May 9, 2019 /PRNewswire/ -- "Initial sales of Buvidal® follows plan and we are expecting to see significant growth during the year" Summary first quarter 2019 Buvidal® launched as the first long-acting medicine for opioid dependence in the EU; with in...
News, Short Squeeze, Breakout and More Instantly...
Camurus AB Company Name:
CAMRF Stock Symbol:
OTCMKTS Market:
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence PR Newswire LUND, Sweden , May 3, 2021 /PRNewswire/ -- Camurus AB (NASDAQ STO: CAMX) today announced that the Australian regulatory agency, the Therapeutic Good...
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire LUND, Sweden , March 26, 2021 /PRNewswire/ -- Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Eu...
Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation Both weekly and daily formulations of setmelanotide were observed to be safe and well-tolerated LUND, Sweden , June 24, 2020 /PRNewswire/ -- Camurus' partner Rhyt...